Compliance updated on Jun 19, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Celyad Oncology SA

CYAD.BR ✓ COMPLIANT ☆ Track — members

Euronext Brussels · Healthcare · Biotechnology & Medical Research ·

Belgium Micro Cap Analyst: HOLD

Last Close

$0.31

▼ -0.37%

Market Cap $14.60M · Vol 11.81K

Key Metrics

P/E Ratio

20.04

FWD: N/A

Market Cap

$14.60M

Micro Cap

Div Yield

0.00%

Annual dividend

EPS Growth

N/A

YoY

RSI (14)

41.03

Momentum

Beta

0.93

vs Market

52W High

$0.75

59.76% below

52W Low

$0.19

64.98% above

Volume

11.81K

Avg 14.42K

P/B

3.12

Price-to-book

ROE

N/A

Return on equity

Free Float

34.30%

Public shares

Shariah Compliance8 STANDARDS

✓ Yes, Celyad Oncology SA (CYAD.BR) stock is Shariah compliant

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does CYAD.BR pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

-0.74%

+7.20%

-7.27%

-18.29%

YTD

+57.65%

-29.84%

-50.63%

-92.65%

Financials & Valuation

TTM · Annual

Total Revenue	$24.66K
Net Income	$974.83K
Revenue Growth (YoY)	-95.93%
Gross Margin	61.90%
Operating Margin	-13,928.57%
Net Profit Margin	3,952.38%
ROE	N/A
ROA · ROIC	11.67% · N/A

P/E Ratio	20.04
Forward P/E (FY1)	N/A
PEG Ratio	0.08
P/S	346.32
P/B	3.12
P/FCF	N/A
EPS Growth	N/A
Outstanding Shares	47.26M

Technical Indicators

50-Day SMA	$0.30
200-Day SMA	$0.30
RSI (14)	41.03
Beta	0.93
52-Week High	$0.75
52-Week Low	$0.19

Volume Today	11.81K
Avg Daily Volume (30D)	14.42K
Relative Volume	0.82x
Volatility (10D)	68.66
Volatility (30D)	85.67
Free Float	34.30%

Analyst Consensus

HOLD

Current Price $0.31

Mean Target N/A

52W Low$0.19 52W High$0.75

Current

Target

$0.19 $0.75

Current Analyst target

· 0 analysts

Identifiers

ExchangeEuronext Brussels

FIGIBBG001T539K9

ISINBE0974260896

CountryBelgium

Sub-IndustryBiotechnology & Medical Research (NEC)

Earnings DateN/A

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

LONN.S Lonza Group AG -1.78% RVMD Revolution Medicines Inc +0.85% ONC BeOne Medicines AG -2.40% 068270.KS Celltrion Inc -0.50% ABVX Abivax SA -2.05%

Company Profile

Celyad Oncology SA, formerly Celyad SA is a Belgium-based company. The Company is a clinical-stage biotechnology company focuses on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer. The Company develops allogeneic and autologous CAR T cell therapy candidates for cancer patients with hematological malignancies and solid tumors. The Company's product, CYAD-101 is a NKG2D receptor-based CAR T, which incorporates non-gene edited allogeneic TIM technology, for the treatment of refractory metastatic colorectal cancer (mCRC). It also develops short hairpin RNA (shRNA)-based allogeneic CAR T candidate CYAD-211 for the treatment of relapsed or refractory multiple myeloma (r/r MM). Its autologous CAR T franchise is evaluating NKG2D receptor CAR T candidate CYAD-02 for the treatment of relapsed or refractory acute myeloid leukemia (r/r AML) and myelodysplastic syndromes (MDS).